DiaSorin S.p.A.. (12/12/17). "Press Release: DiaSorin Launches a New Simplexa Bordetella Direct Molecular Test". Saluggia.

	Organisation	DiaSorin Molecular LLC
	Group	DiaSorin (Group)
	Product	Simplexa Bordetella Direct molecular test
	Product 2	Liaison MDX system
	Person	Tabb, Michelle (DiaSorin 201712 VP RnD at DiaSorin Molecular LLC)
	Person 2	Fava, Riccardo (DiaSorin 201607 IR + Corporate Communications Director)

DiaSorin (FTSE Italia Mid Cap: DIA) receives CE Mark for a new Bordetella molecular diagnostic test. Simplexa Bordetella Direct is designed to quickly provide qualitative detection and differentiation of both Bordetella pertussis and Bordetella parapertussis in human nasopharyngeal swabs. The assay has also been submitted for FDA clearance.

Pertussis, or whooping cough, is a highly contagious disease of the respiratory system caused by small, gram-negative B. pertussis and B.parapertussis bacteria. While most of the cases are caused by B. pertussis, some milder cases have been linked to B. parapertussis. Pertussis can lead to hypoxia, permanent brain damage or death, particularly in infants.

The World Health Organization estimates that there are 50 million whooping cough cases worldwide each year, resulting in 350,000 deaths. According to the 2016 Annual Epidemiological Report on Communicable Diseases in Europe by the European Centre for Disease Prevention and Control, pertussis is the least controlled of the vaccine-preventable diseases. The report also points to a recent resurgence of pertussis.

“We are proud to provide a new assay for the LIAISON MDX instrument for our laboratory partners worldwide,” said Michelle Tabb, Vice President of Research and Development, DiaSorin Molecular LLC. “The addition of the assay further enhances our respiratory menu offering in the marketplace. We are fulfilling our commitment to expand our infectious disease portfolio with the development of new tests aimed at accommodating the shifting needs of today’s laboratories.”

About DiaSorin

Headquartered in Italy and listed in the FTSE Italia Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the “Diagnostic Specialist”.

For additional information, please contact:

Riccardo Fava
Investor Relations & Corporate Communication Senior Director
Tel: +39.0161.487988
riccardo.fava@diasorin.it

Ines Di Terlizzi
Investor Relator
Tel: +39.0161.487567
ines.diterlizzi@diasorin.it

Record changed: 2023-06-05